Barei, F.; Zussino, M.; Tavecchio, S.; Angileri, L.; Rizzo, A.; Calzari, P.; Marzano, A.V.; Ferrucci, S.
Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients. Pharmaceuticals 2024, 17, 117.
https://doi.org/10.3390/ph17010117
AMA Style
Barei F, Zussino M, Tavecchio S, Angileri L, Rizzo A, Calzari P, Marzano AV, Ferrucci S.
Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients. Pharmaceuticals. 2024; 17(1):117.
https://doi.org/10.3390/ph17010117
Chicago/Turabian Style
Barei, Francesca, Martina Zussino, Simona Tavecchio, Luisa Angileri, Arianna Rizzo, Paolo Calzari, Angelo V. Marzano, and Silvia Ferrucci.
2024. "Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients" Pharmaceuticals 17, no. 1: 117.
https://doi.org/10.3390/ph17010117
APA Style
Barei, F., Zussino, M., Tavecchio, S., Angileri, L., Rizzo, A., Calzari, P., Marzano, A. V., & Ferrucci, S.
(2024). Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients. Pharmaceuticals, 17(1), 117.
https://doi.org/10.3390/ph17010117
